It’s an appealing income play to consider Zentalis Pharmaceuticals Inc (ZNTL)

As of close of business last night, Zentalis Pharmaceuticals Inc’s stock clocked out at $13.16, up 3.79% from its previous closing price of $12.68. In other words, the price has increased by $+0.48 from its previous closing price. On the day, 817302 shares were traded.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.


To gain a deeper understanding of ZNTL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.97 and its Current Ratio is at 8.97. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.09.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wedbush on November 08, 2023, Downgraded its rating to Neutral and sets its target price to $12 from $38 previously.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 13 when Blackwell Kimberly bought 5,000 shares for $10.29 per share. The transaction valued at 51,448 led to the insider holds 254,800 shares of the business.

Johnson David Michael bought 17,000 shares of ZNTL for $167,943 on Nov 10. The Director now owns 144,389 shares after completing the transaction at $9.88 per share. On Oct 04, another insider, Brownstein Carrie, who serves as the Chief Medical Officer of the company, sold 10,628 shares for $19.50 each. As a result, the insider received 207,298 and left with 105,685 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZNTL now has a Market Capitalization of 897.31M and an Enterprise Value of 423.94M.

Stock Price History:

Over the past 52 weeks, ZNTL has reached a high of $31.46, while it has fallen to a 52-week low of $9.56. The 50-Day Moving Average of the stock is 13.27, while the 200-Day Moving Average is calculated to be 20.79.

Shares Statistics:

It appears that ZNTL traded 1.09M shares on average per day over the past three months and 625.49k shares per day over the past ten days. A total of 70.77M shares are outstanding, with a floating share count of 63.53M. Insiders hold about 10.23% of the company’s shares, while institutions hold 117.82% stake in the company. Shares short for ZNTL as of Jan 11, 2024 were 13.07M with a Short Ratio of 13.07M, compared to 11.59M on Dec 14, 2023. Therefore, it implies a Short% of Shares Outstanding of 18.47% and a Short% of Float of 25.14%.

Earnings Estimates

As of right now, 11 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.92 for the current quarter, with a high estimate of -$0.61 and a low estimate of -$1.54, while EPS last year was -$0.92. The consensus estimate for the next quarter is -$0.88, with high estimates of -$0.81 and low estimates of -$0.95.

Analysts are recommending an EPS of between -$4.31 and -$5.25 for the fiscal current year, implying an average EPS of -$4.54. EPS for the following year is -$3.76, with 11 analysts recommending between -$3.11 and -$4.51.

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular